Latest filing published 25 Aug 2026 for Teva Pharmaceutical Industries Ltd, €13k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Ronit Satchi-Fainaro (board member) discloses dealings in Teva Pharmaceutical Industries Ltd to SEC (Form 4). The record holds 8 filings, for trades running from 5 June 2021 to 21 August 2026.
The open-market record consists of 1 sale worth €13k, with no purchase. Besides market trades, the filings include 6 option exercises. So far in 2026, the count stands at no purchases and 1 sale.
Most recently, on 25 August 2026, the filings show an open-market sale worth €13k in Teva Pharmaceutical Industries Ltd. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations